CRC
ATXS

Curi RMB Capital’s Astria Therapeutics ATXS Stock Holding History

Curi RMB Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,705
Closed -$435K – 582
2020
Q3 		$435K Hold
11,705
– – 0.02% 442
2020
Q2 		$452K Sell
11,705
-309
-3% -$11K 0.02% 418
2020
Q1 		$299K Buy
12,014
+2,396
+25% +$74.3K 0.01% 489
2019
Q4 		$341K Buy
9,618
+9
+0.1% +$284 0.01% 524
2019
Q3 		$311K Sell
9,609
-494
-5% -$19.5K 0.01% 574
2019
Q2 		$489K Sell
10,103
-580
-5% -$26.3K 0.01% 551
2019
Q1 		$508K Buy
+10,683
New +$362K 0.01% 570

Other funds holding ATXS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Curi RMB Capital's ATXS Position: Q4 2020 in Review

Curi RMB Capital sold out of Astria Therapeutics (ATXS) in Q4 2020, closing a stake of 11,705 shares — an estimated $435K sold.

Curi RMB Capital first reported a position in ATXS in Q1 2019 and held it in 7 quarters. The position peaked at $508K in Q1 2019. 62 funds tracked by Wall St. Rank hold ATXS as of Q4 2020.

  • Curi RMB Capital reported no remaining Astria Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Curi RMB Capital sold 11,705 Astria Therapeutics shares in Q4 2020, an estimated $435K.
  • Curi RMB Capital first reported a position in Astria Therapeutics in Q1 2019 and held it in 7 quarters.
  • Curi RMB Capital's Astria Therapeutics position peaked at $508K in Q1 2019.
  • 62 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2020.

Based on Curi RMB Capital's 13F filing for Q4 2020, filed 11 Feb 2021.